BMO Capital Maintains Bullish 12%+ BrightSpring EBITDA Growth Outlook on Drug Contract Wins, Generic Conversions
BMO Capital Maintains Bullish 12%+ BrightSpring EBITDA Growth Outlook on Drug Contract Wins, Generic Conversions Maham Fatima Mon, December 1, 2025 at 10:35 AM GMT+8 2 min read In this article: BTSG B...